Simplify Logo

Full-Time

Senior/Scientist

RNA Assay Dev

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Biotechnology firm specializing in genetic testing

Biotechnology
Healthcare

Compensation Overview

$108.8k - $163.1kAnnually

Senior

San Bruno, CA, USA

On-site role working out of South San Francisco, CA office.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Required Skills
Excel/Numbers/Sheets
Requirements
  • Doctorate in molecular biology, biochemistry, or closely related field with a minimum of 2 years experience in assay development for the life science industry.
  • Master’s degree in molecular biology, biochemistry, or closely related field with a minimum of 6 years experience in assay development for the life science industry.
  • Bachelor’s degree in molecular biology, biochemistry, or closely related field with a minimum of 8 years experience in assay development for the life science industry.
  • Proven track record of launching RNA-sequencing-based clinical assays or reagent kits (bulk RNA-seq, smRNA-seq, scRNA-seq, etc).
  • Demonstrated success with cross-functional collaborations.
  • Familiarity with laboratory automation and building assays with scale and automation in mind.
  • Must be capable of independently planning and executing complex studies, interpreting results, and making data-driven decisions.
  • Must have experience in optimizing laboratory processes, identifying risks, and troubleshooting issues.
  • Must have good organization and time management skills.
  • Must have experience performing statistical analyses in Excel or similar software. Coding proficiency is a plus.
  • Must be familiar with bioinformatics software commonly used in RNA-sequencing analysis (STAR, samtools, DESeq2, etc.).
  • Must have experience working in a regulated laboratory environment.
Responsibilities
  • Join a team to research, build, and validate high-throughput RNA-sequencing assays.
  • Explore the feasibility of emerging technologies in the RNA-sequencing field.
  • Independently design and execute complex studies, analyze and interpret data, and communicate findings to both scientists and broad audiences.
  • Collaborate with assay development scientists, automation engineers, and computational biologists to develop all aspects of a production-grade clinical assay, including extraction, library preparation, quality control, and analytical pipeline.

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care through accurate genetic insights and early detection of health issues.

Company Stage

IPO

Total Funding

$1.2B

Headquarters

Austin, Texas

Founded

2004

Growth & Insights
Headcount

6 month growth

9%

1 year growth

19%

2 year growth

55%
Simplify Jobs

Simplify's Take

What believers are saying

  • Natera's continuous innovation, such as the launch of the Prospera Heart test with DQS, demonstrates its commitment to improving patient outcomes and maintaining market leadership.
  • The company's diverse product offerings across oncology, transplant health, and women's health provide multiple revenue streams and reduce dependency on a single market.
  • Significant investments from entities like Massachusetts Financial Services Co. MA indicate strong financial backing and confidence in Natera's growth potential.

What critics are saying

  • Allegations of deceptive sales and billing practices could damage Natera's reputation and lead to legal and financial repercussions.
  • The highly competitive nature of the genetic testing market requires constant innovation and differentiation to maintain market share.

What makes Natera unique

  • Natera's focus on cell-free DNA (cfDNA) technology for a wide range of applications, from oncology to prenatal screening, sets it apart from competitors who may specialize in only one area.
  • The introduction of unique features like the Donor Quantity Score (DQS) for transplant rejection detection enhances the accuracy and reliability of their tests, distinguishing them from other genetic testing companies.
  • Natera's extensive portfolio of over 200 peer-reviewed publications underscores its commitment to scientific validation and credibility, which is a significant competitive advantage.

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks